Specialty Pharmacy

Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, explains how pharmacists can counsel patients about risk factors for colorectal cancer and reduction strategies.

Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, discussed emerging trends in oncology care.

In this clip, Bernard Marini, PharmD, BCOP, inpatient hematology specialist at the University of Michigan, discusses how IDH inhibitors like ivosidenib and enasidenib fit into the treatment landscape for patients with relapsed or refractory acute myeloid leukemia.

Each member of the specialty pharmacy care team is an essential component in influencing and ensuring positive outcomes of therapy.

Matthew Malachowski, PharmD, BCPS, supervisor of specialty pharmacy services at UAB Health System, discusses the challenges associated with establishing or expanding specialty pharmacy services within an institution.

Top news of the day from across the health care landscape.

Official with the FDA today granted accelerated approval to erdafitinib (Balversa, Janssen) for adult patients with locally advanced or metastatic bladder cancer.

The expanded first-line indication makes pembrolizumab (Keytruda) monotherapy an option for more patients with non-small cell lung cancer.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the day from across the health care landscape.

There are currently firms working to use artificial intelligence in hopes that it could contribute to minimizing the impact of the opioid epidemic.

Cytomegalovirus may contribute to faster cystic fibrosis progression, but further studies are warranted to confirm these findings.

Top news of the day from across the health care landscape.

The AMCP Managed Care & Specialty Pharmacy Annual Meeting featured various discussions on strategies to manage complex patients and achieve optimal outcomes, highlighted by an exciting string of innovations and policy shifts.

Top news of the day from across the health care landscape.

As specialty pharmacies continue to grow, health systems will need to evaluate whether an integrated specialty pharmacy is right for them.

Romosozumab-aqqg (Evenity, Amgen) works to decrease the risk of fracture by increasing new bone formation in women with postmenopausal osteoporosis.

On Tuesday, a US Senate Finance Committee hearing on drug pricing focused on addressing the role of pharmacy benefit managers (PBMs) in determining cost to patients.

Approximately 1 in 5 patients in a study were misdiagnosed with multiple sclerosis before being referred to treatment centers.

Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut, explains which patient populations would best benefit from either apalutamide versus enzalutamide in the treatment of non-metastatic prostate cancer.

Updated clinical practice guidelines from the National Comprehensive Cancer Network (NCCN) review patient selection for the use of agents such as ibrutinib for the treatment of chronic lymphocytic leukemia.

Top news of the day from across the health care landscape.

Amgen’s ABP 501 (Amjevita) shows similar efficacy to the reference adalimumab (Humira) in treating rheumatoid arthritis and supported approval of the biosimilar by the FDA.

With this approval, patients with HIV who have never been treated have the option of a 2-drug regimen in a single tablet.

Adenosine deaminase is an ultra-rare and inherited disorder that is detrimental to the immune system and causes severe combined immune deficiency.

Brain stem cells of patients with primary progressive multiple sclerosis appear to age faster.

Top news of the day from across the health care landscape.

Physicians who used an electronic health record system found to have a better cognitive workload and performance.

Enfortumab vedotin is being investigated for the treatment of locally advanced or metastatic urothelial cancer following both platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor.